Name: 글로벌 시장 동향
SKU: PH6787
Availability: InStock

보고서 요약(국문)

개요
전 세계 아스페르길루스증 시장은 2022년 32억 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 5.6%의 성장률을 보이며 2030년에는 65억 달러에 이를 것으로 예상됩니다.
전 세계적으로 의료 기술의 발전과 암 치료, 장기 이식, 장기간 면역억제 요법 등으로 면역력이 저하된 인구의 증가가 아스페르길루스증 시장의 성장을 견인하고 있습니다.
아스페르길루스증은 환경에 흔히 존재하는 사상균인 아스페르길루스의 포자를 흡입하여 발생하는 기회 감염으로, 주로 하기도에 영향을 미칩니다. 포자는 발아하여 균사로 자라나 혈관으로 침투하고, 침습성 질환을 유발하여 출혈성 괴사와 경색을 일으킵니다. 증상은 천식, 폐렴, 부비동염 또는 급속히 진행되는 전신 질환과 유사할 수 있습니다.
또한, 전 세계 아스페르길루스증 시장은 새로운 치료법 도입을 위한 연구 개발 증가, 의료비 지출 증가, 탄탄한 제품 파이프라인, 진균 감염 유병률 증가, 의료 전문가 및 일반 대중의 질병 인식 제고, 진단 기술 발전 등 다양한 요인에 의해 성장하고 있습니다.
시장 동향
아스페르길루스증 유병률 증가
아스페르길루스증 유병률 증가는 예측 기간 동안 시장 성장을 촉진하는 중요한 요인 중 하나입니다. 아스페르길루스증은 모든 연령대의 사람들에게 영향을 미치며, 특히 취약 계층에서 심각한 결과를 초래할 수 있습니다. 아스페르길루스증은 면역 체계가 약화된 사람들에게 더 흔하게 발생합니다.
예를 들어, 미네소타 대학교에서 발표한 인도의 심각한 진균 감염 부담에 대한 최신 연구에 따르면, 만성 폐 아스페르길루스증의 연간 발생 건수는 약 212,502건으로 추산되며, 진단 후 1년 이내 사망자는 42,766명에 달합니다. 만성 폐 아스페르길루스증 환자의 약 90%는 폐결핵과 관련이 있으며, 연구진은 전체 유병률을 약 170만 건으로 추정하고 있습니다.
진행 중인 임상 시험 수 증가
진행 중인 임상 시험 수의 증가는 예측 기간 동안 시장 성장을 견인하는 주요 요인 중 하나입니다. 현재 다양한 연구 기관, 연구 기업 및 기타 단체에서 임상 시험이 진행되고 있습니다. 예를 들어, clinicaltrials.gov에 따르면 2022년 3월에 Olorofim Aspergillus Infection Study(OASIS)라는 연구가 기록되어 있는데, 이 연구의 목적은 확진된 침습성 아스페르길루스증(IA) 또는 추정되는 하기도 질환 아스페르길루스 종으로 인한 침습성 진균 감염(IFD) 환자에서 올로로핌 치료와 표준 치료(SOC) 후 암비솜 치료를 비교하는 것이었습니다. 따라서 이 연구는 2025년 3월까지 완료될 것으로 예상됩니다.
또한 clinicaltrials.gov에 따르면 Merck Sharp & Dohme LLC에서 진행 중인 Posaconazole Intravenous and Oral in Children With Invasive Aspergillosis(IA) 연구가 있는데, 이 연구의 목적은 침습성 아스페르길루스증(IA)을 앓고 있는 2세 이상 18세 미만의 소아 환자에서 포사코나졸(POS) 정맥(IV) 및 경구 제형의 안전성, 효능 및 약동학을 평가하는 것입니다. 이 연구는 2024년 4월까지 완료될 것으로 예상됩니다.
아스페르길루스증 관련 합병증
감염 유형에 따라 아스페르길루스증은 다양한 심각한 합병증을 유발할 수 있으며, 이는 예측 기간 동안 시장 성장을 저해하는 요인으로 작용합니다. 몇 가지 예는 다음과 같습니다. 출혈: 아스페르길로마와 침습성 아스페르길루스증 모두 폐에 심각하고 때로는 치명적인 출혈을 일으킬 수 있습니다. 전신 감염: 침습성 아스페르길루스증의 가장 심각한 합병증은 감염이 신체의 다른 부위, 특히 뇌, 심장 및 신장으로 확산되는 것입니다. 침습성 아스페르길루스증은 빠르게 확산되며 치명적일 수 있습니다.
세분화 분석
글로벌 아스페르길루스증 시장은 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
약물 유형 부문에서 이사부코나졸 부문은 아스페르길루스증 시장 점유율의 약 41.7%를 차지했습니다.
약물 유형 부문에서 이사부코나졸 부문은 다음과 같은 점유율을 차지했습니다. 41.7%의 시장 점유율을 차지하고 있으며, 예측 기간 동안에도 이 지역이 지배적인 위치를 유지할 것으로 예상됩니다. 이사부코나졸은 임상적으로 사용 가능한 차세대 트리아졸계 항진균제 중 가장 최근에 개발된 약물로, 다양한 효모, 곰팡이, 이형성 진균에 효과적입니다. 현재 미국 식품의약국(FDA)의 승인을 받은 적응증에는 침습성 아스페르길루스증과 점액진균증 치료가 포함되지만, 점액진균증에 대한 임상 데이터는 제한적입니다.
예를 들어, 감염성 질환 및 암 환자의 요구를 충족하는 데 전념하는 상업 단계의 바이오제약 회사인 바실레아 파마슈티카(Basilea Pharmaceutica Ltd)는 라이선스 파트너인 화이자(Pfizer Inc.)가 중국 국가약품감독관리국(NMPA)으로부터 성인 침습성 아스페르길루스증 환자 치료를 위한 경구용 항진균제 크레셈바(이사부코나졸)의 의약품 승인을 받았다고 발표했습니다.
지역별 시장 점유율
북미, 시장 점유율 약 38.4% 차지
북미는 전체 시장의 약 38.4%를 차지하는 것으로 추정됩니다. FDA 승인, 신제품 출시, 의료 인프라 확충, 다양한 기관 및 연구 산업의 임상 시험 증가와 같은 요인으로 인해 예측 기간 동안 이 지역의 전체 시장 점유율이 증가할 것으로 예상됩니다.
예를 들어, 2023년 8월 아스텔라스 파마 미국 법인(Astellas Pharma US, Inc.)은 미국 식품의약국(FDA)이 아졸계 항진균제인 이사부코나졸의 전구체인 크레셈바(CRESEMBA, 이사부코나조늄 황산염)에 대한 보충 신약 허가 신청(sNDA)을 승인했다고 발표했습니다. 이 신청은 1세에서 17세 사이의 소아 환자의 침습성 아스페르길루스증(IA) 또는 침습성 뮤코르미코시스(IM) 치료를 위한 것입니다. 처방약 사용자 수수료법(PDUFA)에 따라 FDA는 2023년 12월 9일을 승인 예정일로 정했습니다.
경쟁 환경
이 시장의 주요 글로벌 업체로는 화이자(Pfizer), 써마 피셔 사이언티픽(Therma Fisher Scientific), 리와인 파마슈티컬스(Rewine Pharmaceuticals), 테바 파마슈티컬스(Teva Pharmaceuticals) 등이 있습니다. 유지아 파마, 크리슐라 파마슈티컬스, 머크, 아오젤, 히크마, 젤리아 파마슈티컬스 등이 있습니다.

COVID-19 영향 분석
최근 유럽 의학 진균학회(ECMO)와 국제 인간 및 동물 진균학회(ISHAM)의 합의 지침에 따르면, 중증 SARS-CoV-2 감염으로 인한 기도 내벽 손상은 아스페르길루스 곰팡이의 조직 침입을 유발하며, 이는 전 세계 아스페르길루스증 시장에 상당한 영향을 미쳤습니다. 이러한 이차 진균 감염은 환자의 예후를 악화시킬 수 있으며, 1차 치료제인 보리코나졸과 이사부코나졸에 대한 아스페르길루스 내성 발생 가능성에 대한 우려가 제기되고 있습니다.

코로나바이러스(COVID-19) 팬데믹은 또한 의약품 개발, 생산 및 공급에 상당한 영향을 미쳤으며, 북미, 유럽, 아시아 태평양 지역의 여러 제약 회사에서 생산하는 항진균제 및 코르티코스테로이드와 같은 만성 아스페르길루스증 치료제의 성장에 영향을 미쳤습니다.

작성자: 유형
• 만성 폐 아스페르길루스증
• 알레르기성 기관지폐 아스페르길루스증(ABPA)
• 침습성 아스페르길루스증
o 침습성 진균성 비부비동염
o 침습성 폐 아스페르길루스증
약물 종류별
• 이사부코나졸
• 보리코나졸
• 암포테리신-B
• 이트라코나졸
• 코르티코스테로이드
• 포사코나졸
• 기타
투여 경로별
• 경구
• 정맥 주사
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 러시아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
 2023년 6월, Endo International plc는 자사의 Par Sterile Products 사업부가 미국 식품의약국(FDA)의 약식 신약 허가 신청(ANDA) 최종 승인을 받은 후, Merck의 Noxafil의 미국 최초 제네릭 의약품인 포사코나졸 주사제(18mg/mL)의 출하를 시작했다고 발표했습니다. 포사코나졸 주사제는 아스페르길루스 및 칸디다 감염 발생 위험이 높은 환자의 침습성 감염 예방에 사용됩니다.

 2023년 2월, 특허받은 iSPERSE 기술을 사용하여 심각한 질병을 치료하는 혁신적인 흡입 치료제를 개발하는 임상 단계 바이오제약 회사인 Pulmatrix, Inc.는 알레르기성 기관지폐 아스페르길루스증(ABPA) 및 천식 환자를 대상으로 PUR1900의 안전성과 효능을 평가하는 2b상 임상시험에서 첫 번째 환자에게 투약했다고 발표했습니다. PUR1900은 이 회사의 iSPERSE 기술이 적용된 이트라코나졸 건조 분말 제형은 흡입 폐 투여용으로 개발되었습니다.

 2022년 12월, 아사히 카세이 제약은 일본에서 아스페르길루스증, 뮤코르미코시스, 크립토코쿠스증과 같은 진균 감염 치료를 위한 크레셈바 캡슐 100mg과 크레셈바 정맥 주입액 200mg(일반명: 이사부코나조늄 설페이트, 개발 중)의 제조 및 판매 승인을 받았습니다.

보고서 구매 이유:

• 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별 글로벌 아스페르길루스증 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 식별합니다.

• 모든 세그먼트를 포함한 글로벌 아스페르길루스증 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공. 주요 참여 기업.
글로벌 아스페르길루스증 시장 보고서는 약 61개의 표, 58개의 그림, 186페이지로 구성됩니다.
2023년 주요 고객
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Aspergillosis Market reached US$ 3.2 billion in 2022 and is expected to reach US$ 6.5 billion by 2030, growing with a CAGR of 5.6% during the forecast period 2023-2030.
Globally, the prevalence of aspergillosis is increasing as a result of the development of advanced medical practices with a rise in the proportion of immunocompromised populations due to cancer treatment, organ transplantation, and prolonged immunosuppressive therapy helps the Aspergillosis market to grow during the forecast period.
Aspergillosis is an opportunistic infection that usually affects the lower respiratory tract and is caused by inhaling spores of the filamentous fungus Aspergillus, commonly present in the environment. The spores germinate and develop into hyphae, which enter blood vessels and, with invasive disease, cause haemorrhagic necrosis and infarction. Symptoms may be those of asthma, pneumonia, sinusitis, or rapidly progressing systemic illness.
Furthermore, the global aspergillosis market is driven by various factors like a rise in research and development to introduce new and improved treatment options increasing healthcare expenditure, robust product pipeline, rise in increasing prevalence of fungal infections, rising awareness about the disease among healthcare professionals and the general population, and advancements in diagnostic techniques are primary growth drivers for the aspergillosis treatment market.
Dynamics
Rise in the Prevalence of Aspergillosis
The rise in the prevalence of aspergillosis is one of the significant key factors that help the market to grow during the forecast period. Aspergillosis affects individuals of all ages and has severe consequences, particularly in vulnerable populations. Aspergillosis is more common among individuals with weakened immune systems.
For instance, according to the University of Minnesota updated study published on the Burden of serious fungal infections in India. The annual incidence of chronic pulmonary aspergillosis is an estimated 212,502 cases, including 42,766 deaths in the year following diagnosis. About 90% of the chronic pulmonary aspergillosis burden is associated with pulmonary tuberculosis, and the authors estimate that the total prevalence is about 1.7 million cases.
Rise in Number of Ongoing Clinical Trails
The rise in ongoing clinical trials is one of the key factors that helps the market to grow during the forecast period. There are currently ongoing clinical trials which are conducted by various institutes, research industries and others. For instance, according to clinicaltrails.gov in March 2022, there was a study which is recorded titled Olorofim Aspergillus Infection Study (OASIS) where the objective of this study was to compare treatment with olorofim versus treatment with AmBisome followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA. Hence, these studies are estimated to be complete by March 2025.
Additionally, according to clinicaltrails.gov another ongoing study on Posaconazole Intravenous and Oral in Children With Invasive Aspergillosis (IA) which is conducted by Merck Sharp & Dohme LLC where the study objective is to evaluate the safety, efficacy, and pharmacokinetics of Posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA) and this studies are expected to complete by April 2024.
Complications Associated with Aspergillosis
Depending on the type of infection, aspergillosis can cause a variety of serious complications which act as a drawback factor that hamper the market growth during the forecast period. Some of them are Bleeding. Both aspergillomas and invasive aspergillosis can cause severe, and sometimes fatal, bleeding in your lungs. Systemic infection. The most serious complication of invasive aspergillosis is the spread of the infection to other parts of your body, especially your brain, heart and kidneys. Invasive aspergillosis spreads rapidly and may be fatal.
Segment Analysis
The global Aspergillosis market is segmented based on type, drug type, route of administration, distribution channel and region.
The Isavuconazole Segment From the Drug Type Segment Accounted For Approximately 41.7% of Aspergillosis Share
The isavuconazole segment from the drug type segment accounted for 41.7% and it is expected to be dominated during the forecast period. Isavuconazole is the newest of the clinically available advanced-generation triazole antifungals and is active against a variety of yeasts, moulds, and dimorphic fungi. Its current FDA-approved indications include the management of invasive aspergillosis as well as mucormycosis, though the latter indication is supported by limited clinical data
For instance, Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced that its license partner, Pfizer Inc., has received a drug approval license from the National Medical Products Administration (NMPA) in China, for the oral formulation of its antifungal Cresemba (isavuconazole) for the treatment of adult patients with invasive aspergillosis.
Geographical Penetration
North America Accounted for Approximately 38.4% of the Market Share
North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to the factors like FDA approvals, new product launches, rise in the healthcare infrastructure, and rising clinical trials by various institutes and research industries help this region to grow during the forecast period.
For instance, in August 2023 Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for CRESEMBA (isavuconazonium sulfate), a prodrug of isavuconazole, an azole antifungal drug, seeking approval for the treatment of invasive aspergillosis (IA) or invasive mucormycosis (IM) in pediatric patients aged one to 17 years old. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of December 9, 2023.
Competitive Landscape
The major global players in the market include Pfizer, Therma Fisher Scientific, Rewine Pharmaceuticals, Teva Pharmaceuticals, Eugia Pharma, krishlar Pharmaceuticals, Merck, Aozeal, Hikma, Xellia Pharmaceuticals and among others.
COVID-19 Impact Analysis
Covid 19 had a substantial impact on the global Aspergillosis market which damaged the lining of airways from severe SARS-CoV-2 infection allows Aspergillus fungi to invade the tissue, according to a recent consensus guidance from the European Confederation of Medical Mycology and the International Society for Human and Animal Mycology. These secondary fungal infections can worsen patient outcomes, and they’ve raised concern about emerging evidence of Aspergillus resistance to voriconazole and isavuconazole, the first-line therapies.
The coronavirus (COVID-19) pandemic also had a substantial impact on the development, production, and supply of pharmaceutical products and affected the growth of the medication used in the treatment of chronic aspergillosis such as antifungal drugs and corticosteroids manufactured by various companies across the regions such as North America, Europe, and Asia Pacific.
By Type
• Chronic Pulmonary Aspergillosis
• Allergic Bronchopulmonary Aspergillosis (ABPA)
• Invasive Aspergillosis
o Invasive Fungal Rhinosinusitis
o Invasive Pulmonary Aspergillosis
By Drug Type
• Isavuconazole
• Voriconazole
• Amphotericin-B
• Itraconazole
• Corticosteroids
• Posaconazole
• Others
By Route of Administration
• Oral
• Intravenous
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Russia
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
 In June 2023, Endo International plc announced that its Par Sterile Products business has begun shipping posaconazole injection (18 mg/mL), the first generic version of Merck's Noxafil in the U.S., following final approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application. Posaconazole injection is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections.
 In February 2023, Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE technology, announced the first patient dosed in a Phase 2b trial evaluating the safety and efficacy of PUR1900 in subjects with Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. PUR1900 is the company's iSPERSE-enabled dry powder formulation of itraconazole, developed for inhaled pulmonary delivery.
 In December 2022 Asahi Kasei Pharma obtained approval to manufacture and sell Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg (generic name: isavuconazonium sulfate, development) in Japan for treatment of the fungal infections of aspergillosis, mucormycosis, and cryptococcosis.
Why Purchase the Report?
• To visualize the global Aspergillosis market segmentation based on type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global Aspergillosis market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The Global Aspergillosis Market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the Prevalence of Aspergillosis
4.1.1.2. Rise in Number of Ongoing Clinical Trails
4.1.2. Restraints
4.1.2.1. Complications associated with Aspergillosis
4.1.3. Opportunity
4.1.3.1. Rise in Robust Product Pipeline
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Chronic Pulmonary Aspergillosis*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Allergic Bronchopulmonary Aspergillosis (ABPA)
7.4. Invasive Aspergillosis
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Isavuconazole*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Voriconazole
8.4. Amphotericin-B
8.5. Itraconazole
8.6. Corticosteroids
8.7. Posaconazole
8.8. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Therma Fisher Scientific
13.3. Rewine Pharmaceuticals
13.4. Teva Pharmaceuticals
13.5. Eugia Pharma
13.6. krishlar Pharmaceuticals
13.7. Merck
13.8. Aozeal
13.9. Hikma
13.10. Xellia Pharmaceuticals
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Pfizer, 4.	Key Developments, Therma Fisher Scientific, Rewine Pharmaceuticals, Teva Pharmaceuticals, Eugia Pharma, krishlar Pharmaceuticals, Merck, Aozeal, Hikma, Xellia Pharmaceuticals

표 목록 (Tables)

List of Tables

Table 1 Global Aspergillosis Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Aspergillosis Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Aspergillosis Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Aspergillosis Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Aspergillosis Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Aspergillosis Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Aspergillosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 8 Global Aspergillosis Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Aspergillosis Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 10 Global Aspergillosis Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Aspergillosis Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 12 Global Aspergillosis Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Aspergillosis Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 14 Global Aspergillosis Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 15 Global Aspergillosis Market Value, By Region, 2021-2030 (US$ Billion)

Table 16 North America Aspergillosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 17 North America Aspergillosis Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 18 North America Aspergillosis Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 19 North America Aspergillosis Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 20 North America Aspergillosis Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 South America Aspergillosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 22 South America Aspergillosis Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 23 South America Aspergillosis Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 24 South America Aspergillosis Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 25 South America Aspergillosis Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Europe Aspergillosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 27 Europe Aspergillosis Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 28 Europe Aspergillosis Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 29 Europe Aspergillosis Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 30 Europe Aspergillosis Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Asia-Pacific Aspergillosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 32 Asia-Pacific Aspergillosis Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 33 Asia-Pacific Aspergillosis Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 34 Asia-Pacific Aspergillosis Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 35 Asia-Pacific Aspergillosis Market Value, By Country, 2021-2030 (US$ Billion)

Table 36 Middle East & Africa Aspergillosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 37 Middle East & Africa Aspergillosis Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 38 Middle East & Africa Aspergillosis Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 39 Middle East & Africa Aspergillosis Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 40 Pfizer: Overview

Table 41 Pfizer: Product Portfolio

Table 42 Pfizer: Key Developments

Table 43 Therma Fisher Scientific: Overview

Table 44 Therma Fisher Scientific: Product Portfolio

Table 45 Therma Fisher Scientific: Key Developments

Table 46 Rewine Pharmaceuticals: Overview

Table 47 Rewine Pharmaceuticals: Product Portfolio

Table 48 Rewine Pharmaceuticals: Key Developments

Table 49 Teva Pharmaceuticals: Overview

Table 50 Teva Pharmaceuticals: Product Portfolio

Table 51 Teva Pharmaceuticals: Key Developments

Table 52 Eugia Pharma: Overview

Table 53 Eugia Pharma: Product Portfolio

Table 54 Eugia Pharma: Key Developments

Table 55 krishlar Pharmaceuticals: Overview

Table 56 krishlar Pharmaceuticals: Product Portfolio

Table 57 krishlar Pharmaceuticals: Key Developments

Table 58 Merck : Overview

Table 59 Merck: Product Portfolio

Table 60 Merck: Key Developments

Table 61 Aozeal: Overview

Table 62 Aozeal: Product Portfolio

Table 63 Aozeal: Key Developments

Table 64 Hikma: Overview

Table 65 Hikma: Product Portfolio

Table 66 Hikma: Key Developments

Table 67 Xellia Pharmaceuticals: Overview

Table 68 Xellia Pharmaceuticals: Product Portfolio

Table 69 Xellia Pharmaceuticals: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Aspergillosis Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Aspergillosis Market Share, By Drug Type, 2022 & 2030 (%)

Figure 4 Global Aspergillosis Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Aspergillosis Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Aspergillosis Market Share, By 0, 2022 & 2030 (%)

Figure 7 Global Aspergillosis Market Share, By 0, 2022 & 2030 (%)

Figure 8 Global Aspergillosis Market Share, By 0, 2022 & 2030 (%)

Figure 9 Global Aspergillosis Market Share, By 0, 2022 & 2030 (%)

Figure 10 Global Aspergillosis Market Share, By 0, 2022 & 2030 (%)

Figure 11 Global Aspergillosis Market Share, By 0, 2022 & 2030 (%)

Figure 12 Global Aspergillosis Market Share, By Region, 2022 & 2030 (%)

Figure 13 Global Aspergillosis Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 14 Chronic Pulmonary Aspergillosis Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 15 Allergic Bronchopulmonary Aspergillosis (ABPA) Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 16 Invasive Aspergillosis Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 17 Global Aspergillosis Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 18 Isavuconazole Drug Type in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 19 Voriconazole Drug Type in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 20 Amphotericin-B Drug Type in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 21 Itraconazole Drug Type in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 22 Corticosteroids Drug Type in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 23 Posaconazole Drug Type in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 24 Others Drug Type in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 25 Global Aspergillosis Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 26 Oral Route of Administration in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 27 Intravenous Route of Administration in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 28 Global Aspergillosis Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 29 Hospital Pharmacies Distribution Channel in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 30 Retail Pharmacies Distribution Channel in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 31 Online Pharmacies Distribution Channel in Global Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 32 Global Aspergillosis Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 33 North America Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 34 Asia-Pacific Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 35 Europe Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 36 South America Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 37 Middle East and Africa Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 38 North America Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 39 North America Aspergillosis Market Share, By Type, 2022 & 2030 (%)

Figure 40 North America Aspergillosis Market Share, By Drug Type, 2022 & 2030 (%)

Figure 41 North America Aspergillosis Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 42 North America Aspergillosis Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 43 North America Aspergillosis Market Share, By Country, 2022 & 2030 (%)

Figure 44 South America Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 45 South America Aspergillosis Market Share, By Type, 2022 & 2030 (%)

Figure 46 South America Aspergillosis Market Share, By Drug Type, 2022 & 2030 (%)

Figure 47 South America Aspergillosis Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 48 South America Aspergillosis Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 49 South America Aspergillosis Market Share, By Country, 2022 & 2030 (%)

Figure 50 Europe Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 51 Europe Aspergillosis Market Share, By Type, 2022 & 2030 (%)

Figure 52 Europe Aspergillosis Market Share, By Drug Type, 2022 & 2030 (%)

Figure 53 Europe Aspergillosis Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 54 Europe Aspergillosis Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 55 Europe Aspergillosis Market Share, By Country, 2022 & 2030 (%)

Figure 56 Asia-Pacific Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 57 Asia-Pacific Aspergillosis Market Share, By Type, 2022 & 2030 (%)

Figure 58 Asia-Pacific Aspergillosis Market Share, By Drug Type, 2022 & 2030 (%)

Figure 59 Asia-Pacific Aspergillosis Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 60 Asia-Pacific Aspergillosis Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 61 Asia-Pacific Aspergillosis Market Share, By Country, 2022 & 2030 (%)

Figure 62 Middle East & Africa Aspergillosis Market Value, 2021-2030 (US$ Billion)

Figure 63 Middle East & Africa Aspergillosis Market Share, By Type, 2022 & 2030 (%)

Figure 64 Middle East & Africa Aspergillosis Market Share, By Drug Type, 2022 & 2030 (%)

Figure 65 Middle East & Africa Aspergillosis Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 66 Middle East & Africa Aspergillosis Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 67 Pfizer: Financials

Figure 68 Therma Fisher Scientific: Financials

Figure 69 Rewine Pharmaceuticals: Financials

Figure 70 Teva Pharmaceuticals: Financials

Figure 71 Eugia Pharma: Financials

Figure 72 krishlar Pharmaceuticals: Financials

Figure 73 Merck: Financials

Figure 74 Aozeal: Financials

Figure 75 Hikma: Financials

Figure 76 Xellia Pharmaceuticals: Financials

세계 아스페르길루스증 시장 – 2023-2030

Global Aspergillosis Market - 2023-2030